## Jingxin Fu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4324461/publications.pdf

Version: 2024-02-01

933447 1281871 6,262 12 10 11 citations h-index g-index papers 14 14 14 5242 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nature Medicine, 2018, 24, 1550-1558.	30.7	2,791
2	TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Research, 2020, 48, W509-W514.	14.5	2,546
3	Large-scale public data reuse to model immunotherapy response and resistance. Genome Medicine, 2020, 12, 21.	8.2	514
4	Landscape of B cell immunity and related immune evasion in human cancers. Nature Genetics, 2019, 51, 560-567.	21.4	115
5	Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. Cancer Discovery, 2021, 11, 1524-1541.	9.4	103
6	InÂvivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. Cell, 2021, 184, 5357-5374.e22.	28.9	79
7	TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response. Nucleic Acids Research, 2022, 50, D1391-D1397.	14.5	41
8	Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors. Clinical Cancer Research, 2020, 26, 5990-6002.	7.0	28
9	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood, 2021, 137, 3212-3217.	1.4	24
10	Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. Genome Biology, 2020, 21, 263.	8.8	15
11	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. Clinical Cancer Research, 2021, 27, 5049-5061.	7.0	6
12	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. Clinical Cancer Research, 2021, 27, 5049-5061.	7.0	0